Daily Archives: January 18, 2018
P062 INTEGRIN ß7 DEFICIENCY RESULTS IN PAUCITY OF TERTIARY LYMPHOID TISSUES AND DECREASED LAMINA PROPRIA IGA+ B CELLS LEADING TO MICROBIOME DYSBIOSIS AND WORSE INFLAMMATION IN A MODEL OF CROHN’S-LIKE ILEITIS
Integrin α4β7 expression on lymphocytes promotes their localization to the gut. A monoclonal antibody against these integrins (i.e. vedolizumab) is safe and effective treatment for inflammatory bowel disease (IBD). Given the importance of integrins o… Continue reading
P128 USE OF QUALITY IMPROVEMENT PROCESS TO INCREASE INFLUENZA VACCINATION IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
Patients with inflammatory bowel disease (IBD) on immunosuppression are at increased risk for contracting influenza. Our study was a quality improvement (QI) initiative to improve the rate of influenza vaccination and electronic medical record (EMR) do… Continue reading
P061 INFLAMMATORY BOWEL DISEASE SEVERITY INFLUENCES VITAMIN D MONITORING
It has been suggested that vitamin D has a role in the pathogenesis and regulation of inflammatory bowel disease (IBD). However, physicians inconsistently obtain vitamin D levels in IBD patients for unclear reasons. It is speculated that the severity o… Continue reading
P126 TRANSVERSE MYELITIS AFTER VEDOLIZUMAB INDUCTION
A 36-year-old woman with ankylosing spondylitis (AS) and a 12 year history of moderate, extensive ulcerative colitis (UC) was evaluated for active symptoms after a 15 month hiatus. Prior therapy included mesalamine and infliximab; the latter led to cli… Continue reading
P060 INFLAMMATION-ASSOCIATED COLONIC LYMPHATIC ARCHITECTURE DISRUPTION IS AMELIORATED BY IRISIN A CHRONIC RODENT MODEL OF IBD
The lymphatics are the main transport of lymph (containing fluid, macromolecules, and immunological components such as cells and cytokines) from the parenchymal tissues to the lymph nodes. Inflammation-induced lymphangiogenesis and lymphatic dysfunctio… Continue reading
P124 THE UBIQUITIN EDITING ENZYME A20 LINKS INFLAMMATION AND COLITIS ASSOCIATED CANCER
Inflammatory bowel disease (IBD) patients are at increased risk of colorectal cancer (CRC)1. Tumor initiating events in colitis-associated cancers (CACs) differ significantly from sporadic CRC2. In CACs, hyperactivity of wnt/beta-catenin signaling typi… Continue reading
P059 INDOLEAMINE 2,3-DIOXYGENASE 1 EXPRESSION PROMOTES EPITHELIAL SECRETORY CELL DIFFERENTIATION VIA ARYL HYDROCARBON RECEPTOR
In mouse models of IBD, the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) has been shown to limit disease severity. Our studies indicate that intestinal epithelial cells are an important source of IDO1 expression in these conditio… Continue reading
P122 THE ROLE OF PTPN2 SNP IN THE PATHOGENESIS OF FIBROSIS IN CROHN’S DISEASE
We identified altered IL-6-induced Jak1-dependent STAT3 phosphorylation in human ileal subepithelial myofibroblasts (SEMF) of patients with stricturing Crohn’s disease. This resulted in co-localization of pSTAT3(Y705) to Rab5+ signaling endosomes alo… Continue reading
P058 INCREASES IN HEMOGLOBIN ARE ASSOCIATED WITH A DECREASED RISK FOR COLORECTAL CANCER IN VETERAN’S AFFAIRS INFLAMMATORY BOWEL DISEASE PATIENTS
Colorectal cancer (CRC) has long been associated with inflammatory bowel disease (IBD), thought to be due to chronic mucosal inflammation. With newer IBD treatments, the incidence of CRC is decreasing, possibly due to improved therapies or improved tre… Continue reading
P120 THE ROLE OF MICROBIOTA AND MACROPHAGES DURING COLITIS IN TUMOR NECROSIS FACTOR RECEPTOR 1 (TNFR1) AND IL-10 DEFICIENT MOUSE MODEL
Inflammatory bowel disease (IBD) remain major clinical challenges and are currently incurable. Tumor necrosis factor (TNF) is a major therapeutic target in IBD, and TNFR1 polymorphisms have been described in IBD patients. Interleukin 10 (IL-10) recepto… Continue reading